BioSpace News Archive

In response to the U.S. Department of Health and Human Services (HHS) secretary’s declaration that the 2019 novel coronavirus (COVID-19) outbreak is a public health emergency, leaders of national public health organizations, including the Association of State and Territorial Health Officials (ASTHO), National Association of County and City Health Officials (NACCHO)

ROCKVILLE, Md. , Feb. 24, 2020 /PRNewswire/ -- Vigene Biosciences, Inc. (Vigene), a leading biotechnology company for viral vector production and development for cell and gene therapies, announced the award of a patent from USPTO on recombinantly-modified adeno-associated virus (AAV) helper vectors that are capable of increasing the packaging efficiency of recombinantly-modifi

Kirsten Beronio has joined the National Association for Behavioral Healthcare (NABH) as director of policy and regulatory affairs, effective Feb. 24

NeuLife Rehab in Mount Dora, FL, one of the nation’s leading CARF Accredited residential post-acute rehabilitation centers and the largest free-standing facility of its kind in the southeastern U.S. specializing in the treatment of individuals with brain and spinal cord injuries and diagnoses, announced its new President, Tera Welch, has already made a significant impact since coming on board at NeuLife on January 6, 2020.

Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain institutional investors for the purchase in a registered direct offering of an aggregate of 1,000,000 ordinary shares of the Company at a purchase price of $8.00 per share. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ Coronavirus COVID-19 Test has obtained regulatory clearance to be sold as an in vitro diagnostic (“IVD”) for the diagnosis of SARS-CoV-2 (COVID-19)

LEXINGTON, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the fourth quarter and full year ended December 31, 2019. Fourth Quarter and Recent Business and Financial Performance Highlights Achieved fourth quarter total revenue of $3.1 million and product revenue of $1.6 million, representing increases of 71% and 18% respectively, compared to the prior year period

EMERYVILLE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report fourth quarter and full year 2019 financial results on Wednesday, March 11, 2020, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Wednesday, March 11, 2019 at 4:30 p.m. (ET)/1:30 p.m. (PT). The live audio webcast may be accessed through

Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it will provide a corporate overview and financial results for the quarter and year ended December 31, 2019 by hosting a conference

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) today announced that it will delay its 2019 fourth quarter and full-year earnings release and conference call, previously scheduled for Thursday, February 27, 2020.